A narrower follow-up, since the general answer is now clear:
Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?
Dr.EndoIndy said:The bulks-list asymmetry was the piece I had missed entirely.
This is where I part company with the consensus forming above. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.
Dr.EndoIndy said:The bulks-list asymmetry was the piece I had missed entirely.
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
Worth separating that from compounded supply, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
I would rather be corrected than agreed with, if it comes to it.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.EndoIndy said:The bulks-list asymmetry was the piece I had missed entirely.
This is exactly what I could not find anywhere else. Printing the relevant bit and taking it with me.
Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.